Abstract
Amniocentesis is the most common invasive prenatal diagnostic procedure worldwide. It is a technique of withdrawing amniotic fluid from the uterine cavity using a needle, via a transabdominal approach, under continuous ultrasound guidance, in order to obtain a sample of fetal exfoliated cells, transudates, urine, or secretions. The amniotic fluid contains amniocytes and fetal epithelial cells. Amniotic fluid can be tested directly or grown in culture for various chromosomal, bio-chemical, molecular, and microbial studies. Amniocentesis for genetic testing is generally performed between the gestational age of 16 and 20 weeks. Diagnostic amniocentesis is commonly used for prenatal diagnosis of chromosomal abnormalities, single gene disorders, fetal infection, and intra-amniotic inflammation. Common indications cited are advanced maternal age, positive maternal screening results for aneuploidy, structural abnormality on ultrasound, and inconclusive or positive noninvasive prenatal testing. Pre-procedure counseling and screening ultrasound should always be done before subjecting a woman to amniocentesis. Complete procedure is performed under ultrasound guidance with continuous visualization of the needle under proper aseptic conditions. Post-procedure follow-up includes documentation of fetal viability immediately after the procedure by ultrasound studies, anti-D immunoglobulin (300 g) to be administered to RhD negative women, and house rest for 24 h.
Similar content being viewed by others
References
Nadler HL, Gerbie AB. Role of amniocentesis in the intrauterine detection of genetic disorders. N Engl J Med. 1970;282:596–9.
Theodora M, Antsaklis A, Antsaklis P, Blanas K, Daskalakis G, Sindos M, et al. Fetal loss following second trimester amniocentesis. Who is at greater risk? How to counsel pregnant women. J Matern Fetal Neonatal Med. 2016;29(4):590–5.
Cederholm M, Axelsson O, Sjödén PO. Women’s knowledge, concerns and psychological reactions before undergoing an invasive procedure for prenatal karyotyping. Ultrasound Obstet Gynecol. 1999;14:267–72.
Ferber A, Onyeije CI, Zelop CM, O’ Reilly-Green C, Zelop CM, Divon MY. Maternal pain and anxiety in genetic amniocentesis: expectation versus reality. Ultrasound Obstet Gynecol. 2002;19:13–7.
Cruz-Lemini M, Parra-Saavedra M, Borobio V, Bennasar M, Gonce A, Martinez JM, et al. How to perform an amniocentesis. Ultrasound Obstet Gynecol. 2014;44:727–31.
Towner D, Currier RJ, Lorey FW, Cunningham GC, Greve LC. Miscarriage risk from amniocentesis performed for abnormal maternal serum screening. Am J Obstet Gynecol. 2007;196(608):e1–5.
Wilson RD, Langlois S, Johnson JA. Society of obstetricians and gynaecologists of Canada. Mid-trimester amniocentesis fetal loss rate. J Obstet Gynaecol Can. 2007;29(7):586–95.
Akolekar R, Beta J, Picciarelli G, Ogilvie C, D’Antonio F. Re: risk of miscarriage following amniocentesis and chorionic villus sampling. Ultrasound Obstet Gynecol. 2015;45(6):755–7.
Huang L, Jiang T, Liu C. Fetal loss after amniocentesis: analysis of a single center 7957 cases in China. Clinc Exp Obstet Gynecol. 2016;29(4):590–5.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None.
Rights and permissions
About this article
Cite this article
Dimri, N., Baijal, A. Amniocentesis. J. Fetal Med. 3, 131–135 (2016). https://doi.org/10.1007/s40556-016-0084-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40556-016-0084-0